📰 Alimera Sciences News
Page 5 - Alimera Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alimera Sciences. Real-time updates on events, politics, business and more.
September 11, 2023
- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic...
September 10, 2023
Non-infectious Macular Edema Treatment Market | AbbVie, Alimera Sciences, Allergan
September 5, 2023
ZENTEK LTD. 24 Corporate Court Guelph, Ontario N1G 5G5 NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY...
August 23, 2023
Altium Capital Management LP, a New York-based investment firm, recently made a significant move in the stock market by acquiring a new stake in Alimera Sciences Inc. This article provides an in-depth analysis of the transaction, the profiles of both entities, and the potential implications of this strategic move. On August 15, 2023, Altium Capital Management LP purchased 2,984,803 shares of Alimera Sciences Inc at a price of $3.57 per share. This acquisition had a 7.46% impact on the firm...
August 22, 2023
Alimera Sciences (NASDAQ:ALIM – Get Free Report) and Summit Therapeutics (NASDAQ:SMMT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Profitability This table compares Alimera Sciences and […]
August 18, 2023
Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 47% in...
August 9, 2023
Alimera Sciences ALIM is set to give its latest quarterly earnings report on Thursday, 2023-08-10. Here's what investors need to know before the announcement.…
July 22, 2023
StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report released on Wednesday. The firm issued a buy rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the company. HC Wainwright decreased their price target on Alimera Sciences from $9.00 […]
July 20, 2023
MarkNtel Advisors is dedicated to delivering in-depth & comprehensive market research study. Their reports are known for providing unbiased inform